anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Need for Comprehensive Treatment Program in Pediatric Patients

Olanzapine orally disintegrating tablets are indicated as an integral part of a total treatment program for pediatric patients with schizophrenia and bipolar disorder that may include other measures (psychological, educational, social) for patients with the disorder. Effectiveness and safety of olanzapine orally disintegrating tablets have not been established in pediatric patients less than 13 years of age. Atypical antipsychotics are not intended for use in the pediatric patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders. Appropriate educational placement is essential and psychosocial intervention is often helpful. The decision to prescribe atypical antipsychotic medication will depend upon the healthcare provider’s assessment of the chronicity and severity of the patient’s symptoms [see Indications and Usage (1.3)].

All registered trademarks in this document are the property of their respective owners.

Dispense with Medication Guide available at www1.apotex.com/products/uswww1.apotex.com/products/us
Participants in the Aerobic Exercise Only arm will engage in three separate 20-minute sessions comprised of a 5-minute, resistance-free warm-up, and 15 minutes of moderate stationary aerobic cycling on a Cybex bike #525C (50-70% age-predicted heart rate max). Each session will be followed by 20 minutes of uninterrupted quiet rest. The bike will provide feedback including speed, rotations per minute, and time.
Chickens have undergone genetic improvements in the past few decades to maximize growth efficiency. However, necrotic enteritis (NE), an enteric disease primarily caused by C. perfringens, remains a significant problem in poultry production. A study investigated the differences in intestinal health between the nonselected meat-type chicken Athens Canadian Random Bred (ACRB) and the modern meat-type Cobb 500 broilers (Cobb) when challenged with experimental NE. The study utilized a 2 × 3 factorial arrangement, consisting of two main effects of chicken strain and NE challenge model (nonchallenged control, NC; NE challenge with 2,500/12,500 Eimeria maxima oocysts + 1 × 109C. perfringens, NE2.5/NE12.5). A total of 432 fourteen-day-old male ACRB and Cobb were used until 22 d (8 d postinoculation with E. maxima on d 14, dpi), and the chickens were euthanized on 6 and 8 dpi for the analysis. All data were statistically analyzed using a two-way ANOVA, and Student's t-test or Tukey's HSD test was applied when P < 0.05. The NE12.5 group showed significant decreases in growth performance and relative growth performance from d 14 to 20, regardless of chicken strain (P < 0.01). The ACRB group exhibited significant decreases in relative body weight and relative body weight gain compared to the Cobb group from d 14 to 22 (P < 0.01). On 6 and 8 dpi, both NE challenge groups showed significant decreases in intestinal villus height to crypt depth ratio, jejunal goblet cell count, and jejunal MUC2 and LEAP2 expression (P < 0.01). Additionally, the NE12.5 group had significantly higher intestinal NE lesion score, intestinal permeability, fecal E. maxima oocyst count, intestinal C. perfringens count, and jejunal IFNγ and CCL4 expression compared to the NC group (P < 0.05). In conclusion, NE negatively impacts growth performance and intestinal health in broilers, parameters regardless of the strain.
Although periodic limb movements are prevalent among patients with epilepsy, the exact relationship between these movements and epilepsy remains elusive. Objective: The aim of this work was to study the periodic limb movements among patients with genetic generalized epilepsy in relation to different clinical characteristics and seizure recurrence. Methods: Sixty individuals participated in this study: thirty of them were newly diagnosed with genetic generalized epilepsy and thirty were healthy individuals. Sleep quality was assessed using the Pittsburgh Sleep Quality Index questionnaire, and a standard polysomnographic study was conducted to all subjects. All patients then received sodium valproate in therapeutic doses and were followed up for six months. Electroencephalogram (EEG) was done after the follow-up period and seizure recurrence was assessed. Accordingly, patients were classified into three groups according to clinical seizure recurrence and follow-up EEG findings.

Periodic limb movement index and frequency were compared among the patients' groups and were correlated with different clinical characteristics.
The potential therapeutic effects of carnosic acid (CA) on postinflammatory hyperpigmentation (PIH) were evaluated, including its effects on melanin deposition in zebrafish, melanogenesis and melanosome transfer in skin cells and skin wound healing in mice. Our results demonstrated that CA dose-dependently decreased melanin deposition in the skin of juvenile zebrafishes. It also inhibited melanogenesis in melanoma cells and melanosome transfer to keratinocytes. Next, CA was loaded in a liposome-hydrogel system (LP-GEL) to treat skin wounds in mice. The results showed that CA-LP-GEL, as well as LP-GEL, could accelerate skin wound healing and repair the structure of healing skins in mice. Comparatively, the levels of inflammatory factors (IL-1β and TNF-a) in healing skins were significantly increased by LP-GEL, but reduced by CA-LP-GEL. In addition, Fontana-Masson staining analysis of healing skin showed that the melanoma cells were restored by the treatment of LP-GEL and CA-LP-GEL, while the melanin content was significantly increased only by LP-GEL. Real-time PCR data showed that CA decreased the gene expression related with melanogenesis (MITF, TYR and TRP-1), melanosome transfer (MLPH, Myova and Rab27a) and inflammatory cytokines (IL-1β and TNF-α) in vitro and in vivo. In conclusion, CA could reduce melanin deposition in the skin by inhibiting melanogenesis and melanosome transfer. CA-LP-GEL was found to accelerate skin wound healing and suppress inflammation and hyperpigmentation in mice. These results suggest that CA has a big developing potentiality for PIH treatment.
The invention relates to a prescription of a health preserving pillow and child cloth toy filling material. The prescription utilizes acanthopanax tea as a main material and takes the tea of dry pine leaf, dry leaf and flower of syringa amurensis clove, dry leaf and flower of dahurian rhododendron, dry wild rose flower and leaf and flower of motherwort as an accessory material, and a prepared pillow and cloth toy filling material is filled into a material bag to be placed into a pillow and a toy. Acanthopanax leaves have the regulation effect on a central nerve and balance two nervous processes of excitation and inhibition. The acanthopanax tea prepared by the fresh acanthopanax leaves can regulate the nerve, has tea perfume and is assisted with a natural plant, such as a pine leaf, and the like. The pillow prepared by the material enables people to feel like in a great forest during sleeping on a bed and has the effects of promoting sleep and preserving health. The child cloth toy manufactured by the filling material which is prepared by the acanthopanax tea and the leaves and the flowers of the natural plant has natural flowery perfume and acanthopanax tea perfume and enables children to play in states of healthy environment and fresh air.
Participate in mindfulness exercises prior to urodynamic studies (UDS). As a participant, you will be guided through a mindfulness meditation exercise by a licensed professional. During this exercise you will be asked to focus your attention on your breathing, physical sensations, and thoughts. This exercise will last for approximately 10 minutes.
The present invention relates to a pH sensitive particle, a method of preparation thereof, and a use thereof. More particularly, the invention provides a pH sensitive metal nanoparticle and its use for medical treatment utilizing cell necrosis during photothermal therapy. The pH sensitive metal nanoparticle based on this invention consists of a pH sensitive ligand compound whose charge changes depending on the pH of the metal nanoparticle. The particle can be collected in cells, such as cancer cells which present an abnormal pH environment. The pH sensitive metal nanoparticle based on this invention can induce cell death through a photothermal procedure after aggregation. Therefore, the invention enables medical treatment using cell necrosis for e.g. cancer treatment.
Human neuroinflammatory and neurodegenerative diseases, whose prevalence keeps rising, are still unsolved pathobiological/therapeutical problems. Among others, recent etiology hypotheses stressed as their main driver a chronic neuroinflammation, which is mediated by innate immunity-related protein oligomers: the inflammasomes. A panoply of exogenous and/or endogenous harmful agents activates inflammasomes' assembly, signaling, and IL-1β/IL-18 production and neural cells' pyroptotic death. The underlying concept is that inflammasomes' chronic activation advances neurodegeneration while their short-lasting operation restores tissue homeostasis. Hence, from a therapeutic standpoint, it is crucial to understand inflammasomes' regulatory mechanisms. About this, a deluge of recent studies focused on the NLRP3 inflammasome with suggestions that its pharmacologic block would hinder neurodegeneration. Yet hitherto no evidence proves this view. Moreover, known inflammasomes are numerous, and the mechanisms regulating their expression and function may vary with the involved animal species and strains, as well as organs and cells, and the harmful factors triggered as a result. Therefore, while presently leaving out some little-studied inflammasomes, this review focuses on the "other than NLRP3" inflammasomes that participate in neuroinflammation's complex mechanisms: NLRP1, NLRP2, NLRC4, and AIM2. Although human-specific data about them are relatively scant, we stress that only a holistic view including several human brain inflammasomes and other potential pathogenetic drivers will lead to successful therapies for neuroinflammatory and neurodegenerative diseases.
Participants will receive Computerized Cognitive Training and anodal tDCS daily for one month. Stimulation will consist of 20 min of anodal 2mA tDCS stimulation over the DLPFC, followed by 15 min of computerized cognitive training.
BACKGROUND: Sweet sorghum is used mainly as an energy crop and feed crop in arid and semiarid regions, and ensiling is a satisfactory method for preserving high-quality sweet sorghum. The aim of this study was to reveal the dynamics of the fermentation quality, bacterial communities, and fermentation weight loss (FWL) of sweet sorghum silage during fermentation.
METHODS: Sweet sorghum was harvested at the first inflorescence spikelet stage and ensiled without (CK) or with lactic acid bacterial (LAB) additives (L). After ensiling, samples were collected on days 0, 1, 3, 5, 15, 40, and 100 to assess the fermentation quality, bacterial communities, and FWL.
RESULTS: For CK and L, on day 1, the pH was 5.77 and 5.57, respectively, and the lactic acid (LA) was 1.30 and 2.81 g/kg dry matter (DM), respectively. Compared with CK, L had a lower pH and higher LA from days 1 to 5 (P < 0.05), a lower FWL from days 5 to 100 (P < 0.05), and a greater abundance of Lactiplantibacillus from days 1 to 15 (P < 0.05). The main bacterial genera were Leuconostoc and Weissella in CK and Lactiplantibacillus, Leuconostoc, and Weissella in L on day 1; Lactiplantibacillus in all silages from days 3 to 40; and Lactiplantibacillus and Lentilactobacillus in all silages on day 100.
CONCLUSIONS: Sweet sorghum silage fermented relatively slowly during the first day. Moreover, inoculation with LAB accelerated fermentation and optimized bacterial communities during the initial fermentation phase. Inoculation with LAB also reduced the silage FWL, and the LAB succession relay occurred in the silage throughout the fermentation process.
Various infection control measures implemented during the coronavirus disease (COVID-19) pandemic have reduced the number of respiratory infections, which are the most common cause of chronic obstructive pulmonary disease (COPD) exacerbations. Here, we investigated whether infectious disease prevention during the COVID-19 pandemic reduced COPD exacerbations and the characteristics of patients exhibiting exacerbations before and during the COVID-19 pandemic. We included outpatients and inpatients with moderate or severe COPD exacerbations who required systemic steroids between April 1, 2018 and March 31, 2022. Their medical records were retrospectively compared and analyzed in 2-year intervals (before and during the COVID-19 pandemic). During the 4-year observation period, 70,847 outpatients and 2,772 inpatients were enrolled; 55 COPD exacerbations were recorded. The number of COPD exacerbations decreased from 36 before to 19 during the COVID-19 pandemic. Regarding the characteristics of patients with exacerbations, the % forced expiratory volume in one second (52.3% vs. 38.6%, P = 0.0224) and body mass index (BMI) (22.5 vs. 19.3, P = 0.0127) were significantly lower during the COVID-19 pandemic than before the pandemic. The number of COPD exacerbations during the pandemic decreased. Additionally, the tendency for a reduction in COPD exacerbation was greatest in patients with preserved lung function or above-standard BMI patients.
The 200 study participants of this arm will first receive 6 months of nutritional counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
The invention aims at providing a new castle disease and H9 subtype bird flu bivalent vaccine. The new castle disease and H9 subtype bird flu bivalent vaccine contains antigens and adjuvant. The antigens are inactivated H9 subtype bird flu viruses and new castle disease viruses. The H9 subtype bird flu viruses are QDY strains, and the preservation number of the H9 subtype bird flu viruses is CCTCC v201517. The QDY strains of the H9 subtype bird flu viruses and a Lasota strain of the new castle disease viruses are inoculated to chick embryos respectively, and then virus liquid is collected; the virus liquid and the oil adjuvant are mixed and emulsified into the vaccine after the virus liquid is inactivated through a formaldehyde solution. The new castle disease and bird flu bivalent inactivated vaccine is good in immunogenicity, antibody production is fast after immunity, the produced antibody titer is high, the produced antibody holding time is long, the retention period is long, the immunizing dose is small, the selected adjuvant is easy to inject, and two kinds of diseases can be prevented through one-time injection. The vaccine has the advantages of being efficient and good in safety.
Disclosed are monoclonal antibodies against lens epithelial cells and methods of producing them. Continuous cell lines for producing monoclonal antibodies to lens epithelial cells are disclosed. Human lens epithelial antibody producing cells are fused with myeloma cells to provide a fused hybrid, the hybrid is cultured, and antibodies specific to human lens epithelial cells are collected. Proliferation of remnant lens epithelial cells after extracapsular extraction is prevented by instilling the monoclonal antibodies specific to lens epithelial cells into the anterior chamber of the human eye and allowed to interact with the lens epithelial cells. Complement is then instilled into the anterior chamber to cause lysis or other damage to the lens epithelial cells thereby preventing them from multiplying and migrating to cover the surface of the lens capsule left in place. This can be done at the time of extracapsular cataract extraction or later to remove a second cataract caused by proliferation of these cells. There is no damage to other parts of the eye, but only to the remnant lens epithelial cells.
The efficacy of NICOTROL Inhaler therapy as an aid to smoking cessation was demonstrated in two single-center, placebo-controlled, double-blind trials with a total of 445 healthy patients. The number of NICOTROL Inhaler cartridges used was a minimum dose of 4 cartridges/day and a maximum dose of 20 cartridges/day. In both studies, the recommended duration of treatment was 3 months; however, the patients were permitted to continue to use the product for up to 6 months, if they wished. The quit rates are the percentage of all persons initially enrolled who continuously abstained after week 2. NICOTROL Inhaler was more effective than placebo at 6 weeks, 3 months and 6 months. The efficacy is shown in the following table.

Patients who used NICOTROL Inhaler had a significant reduction in the "urge to smoke", a major nicotine withdrawal symptom, compared with placebo-treated patients throughout the first week, (see Figure 1).
Background: Scar formation after trauma and surgery involves an inflammatory response and can lead to the development of chronic pain. Neurotropin® (NTP) is a nonprotein extract of inflamed skin of rabbits inoculated with vaccinia virus. It has been widely used for the treatment of chronic pain. However, the in vivo effects of NTP on painful scar formation have not been determined. To investigate the molecular mechanisms underlying the effects of NTP on the inflammatory response, we evaluated gene expression in the scar tissues and dorsal root ganglions (DRGs) of mice administered NTP and control mice. Methods and results: Mice injected with saline or NTP were used as controls; other mice were subjected to surgery on the left hind paw to induce painful scar formation, and then injected with saline or NTP. Hind paw pain was evaluated by measuring the threshold for mechanical stimulation using the von Frey test. The paw withdrawal threshold gradually returned to pre-operative levels over 4 weeks post-operation; NTP-treated mice showed a significantly shortened recovery time of approximately 3 weeks, suggesting that NTP exerted an analgesic effect in this mouse model. Total RNA was extracted from the scarred hind paw tissues and DRGs were collected 1 week post-operation for a microarray analysis. Gene set enrichment analysis revealed that the expression of some gene sets related to inflammatory responses was activated or inhibited following surgery and NTP administration. Quantitative real-time reverse transcription-polymerase chain reaction analysis results for several genes were consistent with the microarray results. Conclusion: The administration of NTP to the hind paws of mice with painful scar formation following surgery diminished nociceptive pain and reduced the inflammatory response. NTP inhibited the expression of some genes involved in the response to surgery-induced inflammation. Therefore, NTP is a potential therapeutic option for painful scar associated with chronic pain.
The present invention discloses a method for preparing an acanthopanax injection. Both an ethanol extraction method and a water extraction method are adopted for respectively extracting total glycosides ingredients and polysaccharide active ingredients in acanthopanax. The total glycosides ingredients are purified and refined by a macroporous adsorptive resin column, and purification and trash extraction are carried out to polysaccharide ingredients by an aqueous extract and ethanol sedimentation method. Simultaneously, hollow fibre columns are adopted for ultrafiltration and concentration for removing small molecules, and active components with drug effect activity in the acanthopanax are sufficiently reserved. On the basis of comprehensive extraction to active components of acanthopanax by the present invention, purification for discarding the dross and selecting the essential is simultaneously carried out, so the quality of the acanthopanax preparation and the curative effect can be further enhanced. The acanthopanax injection preparation prepared by the method of the present invention has the advantages of high active ingredient content and conspicuous curative effect.
Sprayable compositions, for topical oral application, comprise an aqueous solution containing lobeline sulphate and a topically active local anaesthetic.  Suitable such anaesthetics are ethyl aminobenzoate (benzocaine), lidocaine, or pramoxine hydrochloride. Other active ingredients may be present, such as a non-toxic bactericide, preferably a quarternary ammonium salt such as cetyl dimethylbenzyl ammonium chloride; a surface active agent such as polyoxyethylene sorbitan monolaurate; and aromatic oils, such as oil of pepermint.  Also present may be ethanol, glycerol, buffers such as dibasic sodium phosphate, sweetening agents (e.g. saccharine or sodium cyclamate) and colouring substances.  The compositions are useful for reducing the desire for smoking tobacco.
After the intensive 5-days rehabilitation treatment (2 hours/day, 5 days/week, for 1 week), the EG pa-tients will be encouraged to perform the self-management plan at home with the same duration and in-tensity as the CG (1 hour/session, 3 sessions/week, 12 weeks) through a Digital Telemedicine platform (Phoema GPI Platform, GPI Spa, Trento, Italy). The platform will be implemented with wearable digital devices Axivity AX3, 3-axis Logging Accel-erometer to gather objective and subjective information on the patient's motor activity. At discharge (T1), each patient in the experimental group will receive 2 wearable sensors (Axivity AX3,) for moni-toring of movement data (i.e., activity level, number of steps, distance travelled). The data will be transmitted periodically to the research center and processed. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level.
Su Jok will be applied to the reflection points on the hand based on the painful area of the individual. The painful areas will be determined with the applicator and black pepper seeds will be placed on these areas. Circular massage will be applied to the areas where the seeds are located for 30 minutes.
Self-assembled microparticles with a multi-lamellar structure, comprising an acid with two or more acid groups and an organic base where the molar ratio of acid to basic groups is from 0.6 to 1.4:1. The microparticle may be 0.5-10 microns in size, and the acid may comprise a bis-acid. The microparticles can be used as a particulate support and can be obtained by contacting a bis-acid and organic base in a hydrophilic solvent, wherein the acid is insoluble/sparingly soluble, and the base is soluble. Preferably, the hydrophilic solvent comprises an aqueous solution or a water-in-oil emulsion. The acid can comprise a bis-carboxylic fatty acid with terminal carboxylic acids linked by a hydrophobic region. The acid groups may also be separated by a saturated or unsaturated aliphatic chain which can be substituted. Preferably, the acid comprises brassylic acid, sebacic acid and/or azelaic acid. The base may comprise an aliphatic amine or an aromatic amine, any nitrogen-containing base, one or more of an alkylated amine and an alkylated polyamine, N-methylmorpholine, N,N-dimethylaminoethanol, 4-dimethylaminopyridine, imidazole, PDAC, DDAC, DDPT, and poly epsilon lysine. A macroporous material, a medical diagnostic, and use of the microparticles in antimicrobial compositions, cell culture, and wound dressings are also described.